VIICTR
Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (1)
The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.
The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer. Clin Cancer Res. 2017 Sep 15; 23(18):5489-5501.
View in:
PubMed
subject areas
Animals
Carcinoma, Non-Small-Cell Lung
Cell Line, Tumor
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Disease Models, Animal
Drug Resistance, Neoplasm
Gene Expression Profiling
Hepatocyte Growth Factor
Humans
Hypoxia
Kaplan-Meier Estimate
Lung Neoplasms
Male
Mice
Molecular Targeted Therapy
Multicenter Studies as Topic
Neovascularization, Pathologic
Prognosis
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-met
Receptors, Vascular Endothelial Growth Factor
Signal Transduction
Xenograft Model Antitumor Assays
authors with profiles
IGNACIO IVAN WISTUBA
JOHN VICTOR HEYMACH
WEIYI PENG
MARIA ANGELICA ABDALLA CORTEZ